ClinicalTrials.gg
RecruitingNCT07659301Updated Nov 6, 2026

Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling

An interventional study of Post-exercise Recovery in Athletic Performance, Hyperbaric Oxygenation and Physical Endurance, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Université Catholique de Louvain · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Fatigue with a site in Belgium — 10 open to participants now, 13 under way, 4 of them phase 3. Fatigue · Belgium.

Planned enrollment
19th of 34
48 · median 58
Started
2026
with 4 others
No phase
24 of 47
5 open now
Primary completion
2027-12
later than 10 of 12 live
Registered
44th of 47
by date

Among the 47 studies in Fatigue with a site in Belgium, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2026, is one of 24 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 44th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

10 of the 47 studies in Fatigue with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Fatigue with a site in Belgium, or all of them as a file.
02

Study summary

This study examines whether exposition to hyperbaric oxygen after a road-race simulation can help competitive cyclists recover and perform better the following day.

Hyperbaric oxygen, which involves breathing oxygen inside a pressurized chamber, is used as a recovery method in elite and professional sport. Its effectiveness, however, remains controversial: despite this widespread use, there is a lack of solid scientific evidence that a single HBO session after strenuous endurance exercise actually improves recovery, or that clarifies how the amount of oxygen exposure influences any benefit.

The study includes healthy male road cyclists between 18 and 40 years of age who compete at the national level in Belgium. After completing a fatiguing cycling session, each participant is randomly assigned to one of four groups receiving different levels of oxygen exposure during recovery.

Two groups breathe oxygen under increased pressure inside a chamber at either 2.5 or 1.4 atmospheres absolute. A third group breathes oxygen at normal pressure. The fourth group receives a sham condition that reproduces the treatment setting without active oxygen exposure.

The study is double-blind, meaning that neither the participants nor the researchers assessing the outcomes know which condition each participant receives.

The main goal is to determine whether a single session of post-exercise HBO improves next-day endurance performance, and whether higher oxygen exposure produces greater effects.

The researchers also collect blood samples and physiological measurements to better understand how the body recovers.

03

Conditions studied

  • Athletic Performance
  • Hyperbaric Oxygenation
  • Physical Endurance
  • Muscle Fatigue
  • Oxidative Stress

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Road cyclists competing in Elite 2 (Elite without professional contract) or Under-23 (U23) categories or equivalent [Participation in national-level Belgian competitions within the previous 12 months. No specific ranking, finishing position, or performance threshold is required.]
  • ≥ 2 consecutive years of cycling experience at regional or national level, with structured and periodized training
  • Cycling-specific training volume ≥ 8 h a week over the preceding 10 weeks
  • Stable training load in the weeks preceding inclusion, with no major changes due to injury, illness, or abnormal overload
  • Measured VO₂max ≥ 60 ml/kg/min

Exclusion criteria

Exclusion Criteria:

  • Presence of significant cardiovascular, pulmonary, neurological, ENT, or metabolic disease, including but not limited to: Uncontrolled arterial hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg) ; Unstable heart disease or decompensated cardiomyopathy
  • to hyperbaric exposure, including: Untreated pneumothorax, History of spontaneous pneumothorax without medical clearance ; Pulmonary conditions associated with air trapping (e.g. emphysema or bullous lung disease), or abnormal thoracic imaging when indicated ; Recent thoracic surgery
  • Neurological contraindications, including epilepsy, history of oxygen-induced seizures, or recent seizure activity, and any association with cannabis use
  • Ear, sinus, or Eustachian tube disorders preventing adequate pressure equalization, including active infection or history of severe barotrauma
  • Severe claustrophobia incompatible with chamber exposure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    HBO 2.5 ATA

    PiO₂ = 2.5 (100 % O₂ x 2.5 ATA)

    Other: Post-exercise Recovery

  • Experimental
    HBO 1.4 ATA

    PiO₂ = 1.4 (100 % O₂ x 1.4 ATA)

    Other: Post-exercise Recovery

  • Experimental
    NBO 1.0 ATA

    PiO₂ = 1.0 (100 % O₂ x 1.0 ATA)

    Other: Post-exercise Recovery

  • Sham comparator
    SHAM

    PiO₂ = 0.21 (21 % O₂ x 1.0 ATA)

    Other: Post-exercise Recovery

Interventions

  • OtherPost-exercise Recovery

    1h intervention after a fatiguing exercise

06

What researchers measure

Primary outcomes

  1. Next-day endurance performance : Percent decrement in time to exhaustion from baseline

    Endurance performance measured by a cycling time-to-exhaustion test at 105% of the lactate threshold power, expressed as the percentage decrement in time to exhaustion relative to the baseline test. Performance is compared SHAM to the other oxygen-exposure groups.

    Time frame: Throughout the entire study, approximately during 18 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Neuroscience, Université catholique de Louvain
    Louvain-la-Neuve, Brabant-Wallon 1348, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 17 months is above that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659301
Collaborators
Murdoch University
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Théo A MAHY, MSc
Contact
theo.mahy@uclouvain.be
+32 10 474 489

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion